Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.44 |
| ▸ | TNNI3K | Q59H18 | 4/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 4/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | KIF5B | P33176 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1321972 | 0.77 | RET (0.60) | EGFRERBB3RETKIF5BKDR | |
| SCHEMBL3421008 | 0.74 | TNNI3K (0.52) | EGFRTNNI3KERBB3CDK4CDK2 | |
| SCHEMBL415816 | 0.73 | RET (0.47) | EGFRTNNI3KERBB3RETKIF5B | |
| SCHEMBL15486963 | 0.73 | RET (0.54) | EGFRTNNI3KERBB3RETKIF5B | |
| SCHEMBL2175687 | 0.67 | EGFR (0.57) | EGFRERBB3POLB | |
| SCHEMBL7777444 | 0.67 | EGFR (0.57) | EGFRERBB3KDRAURKAAURKB | |
| SCHEMBL2064298 | 0.66 | KMT2A (0.43) | POLB | |
| SCHEMBL27625432 | 0.65 | KDR (0.52) | EGFRERBB3RETKIF5BKDR | |
| SCHEMBL7777464 | 0.65 | EGFR (0.61) | EGFRERBB3KDRBRAFRAF1 | |
| SCHEMBL15486220 | 0.64 | USP2 (0.72) | CDK4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824856-B1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-23 | — | — | EP | disclosed |
| US-8148388-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR1H3, NR1H2, NR0B1 | EGFR 1611/4885TNNI3K 4409/4885ERBB3 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.